An observational study in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), sponsored by Stemline Therapeutics, Inc.. Recruiting at 41 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Stemline Therapeutics, Inc. (part of Menarini Group) · Observational
The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.
45 studies on the registry are indexed under Blastic Plasmacytoid Dendritic Cell Neoplasm; 15 are open to participants now.
Browse Blastic Plasmacytoid Dendritic Cell Neoplasm studies →Stemline Therapeutics, Inc. is the lead sponsor of 23 studies on the registry; 7 are open to participants now.
First submitted after Stemline Therapeutics, Inc. became part of Menarini Group.
Counted across the registry records on this site, refreshed daily.
Adult participants with BPDCN who are to be treated (or have recently started treatment) with tagraxofusp as first-line therapy according to the European Union summary of product characteristics in standard clinical practice setting across Europe. Participants who are relapse/refractory to prior treatment will also be investigated.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-specified criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult participants with BPDCN prescribed tagraxofusp as a first-line treatment.
Drug: Tagraxofusp
Adult participants with BPDCN prescribed tagraxofusp who are relapsed/refractory to prior treatment.
Drug: Tagraxofusp
No study medication will be provided by the sponsor during this study.
Also known as: ELZONRIS
Number of Participants Achieving Complete Response After 3 Months (+/- 1 month) of Treatment
Time frame: Up to Month 4
Number of Participants Experiencing Capillary Leak Syndrome
Time frame: Up to Month 51
Number of Participants Who Receive Stem Cell Transplant (SCT)
Time frame: Up to Month 66
Progression-free Survival (PFS)
Time frame: Up to Month 66
Overall Survival (OS)
Time frame: Up to Month 66
Best Overall Response (BOR)
Time frame: Up to Month 66
Duration of Response (DOR)
Time frame: Up to Month 66
Number of Participants with Dose Interruptions and/or Requiring Administration of Intravenous Albumin Supplementation
Time frame: Up to Month 66
Number of Participants with Adverse Events of Special Interest (AESI)
Time frame: Up to Month 66
Number of Participants with Adverse Events (AEs)
Time frame: Up to Month 66
Number of Doses/Cycles of Tagraxofusp Administered
Time frame: Up to Month 66
Plan to share: No — No plan to share data.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Blastic Plasmacytoid Dendritic Cell Neoplasm →